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Fistula treatment: The unresolved challenge
Abstract
In population-based studies, up to 50% of patients with Crohn's disease suffer from fistulas. Fistulas
pose a considerable morbidity including permanent sphincter and perineal tissue destruction as well as
professional and personal disabilities. Treatment options have progressed in recent years and fistula
closure and fibrosis of the fistula track is achieved in some patients. Depending on severity of symptoms
and fistula location, different medical and surgical therapies can be chosen. Internal fistulas such as
ileoileal or ileocecal fistulas are either asymptomatic and do not require intervention or they are
symptomatic and need surgery alone. They always carry a risk of abscess formation. Symptomatic
perianal fistulizing disease can be treated with antibiotics (i.e. metronidazole and ciprofloxacin) for
three months and/or immunosuppressant therapy (6-mercaptopurine or azathioprine). More complex
cases require therapy with anti-TNF agents. Only few and preliminary data exist on cyclosporine A,
tacrolimus or methotrexate in fistulizing Crohn's disease. Therefore, these therapies should mainly be
used as second-line therapies. Surgery is reserved for the treatment of perianal sepsis in the presence of
abscesses and refractory disease or complications of fistulas, or used in combination with
pharmacological approaches. The surgical interventions in perianal disease consist of surgical drainage
with or without seton placement, transient ileostomy, or in severe cases, proctectomy. The classification
of fistulas in patients with Crohn's disease remains poorly defined and largely investigator dependent.
The unresolved challenges in fistula treatment warrant randomized controlled trials for existing and
future treatment strategies as well as a better classification system to compare available studies.
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macological approaches. The surgical interventions in peri-
anal disease consist of surgical drainage with or without se-
ton placement, transient ileostomy, or in severe cases, proc-
tectomy. The classification of fistulas in patients with Crohn’s 
disease remains poorly defined and largely investigator de-
pendent. The unresolved challenges in fistula treatment 
warrant randomized controlled trials for existing and future 
treatment strategies as well as a better classification system 
to compare available studies.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Fistulas in Crohn’s disease (CD) patients are often 
troublesome, mainly because of the limited treatment op-
tions available. These fistulas often cause impairment in 
quality of life for CD patients, with serious clinical and 
psychological consequences. In population-based co-
horts, the cumulative incidence of fistula formation has 
been evaluated between 17 and 50%  [1–6] . In a study fol-
lowing Crohn’s patients between 1970 and 1995, Schwartz 
et al. reported a fistula occurrence of 35% over time  [3] . 
Of those fistulas, 54% were perianal, 24% enteroenteric, 
9% rectovaginal, and 13% involved other locations such 
as enterocutaneous, enterovesical, and intraabdominal 
fistulas. In this study, the cumulative incidence of fistulas 
was 33% 10 years after the diagnosis of CD and 50% after 
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 Abstract 
 In population-based studies, up to 50% of patients with 
Crohn’s disease suffer from fistulas. Fistulas pose a consider-
able morbidity including permanent sphincter and perineal 
tissue destruction as well as professional and personal dis-
abilities. Treatment options have progressed in recent years 
and fistula closure and fibrosis of the fistula track is achieved 
in some patients. Depending on severity of symptoms and 
fistula location, different medical and surgical therapies can 
be chosen. Internal fistulas such as ileoileal or ileocecal fistu-
las are either asymptomatic and do not require intervention 
or they are symptomatic and need surgery alone. They al-
ways carry a risk of abscess formation. Symptomatic perianal 
fistulizing disease can be treated with antibiotics (i.e. metro-
nidazole and ciprofloxacin) for three months and/or immu-
nosuppressant therapy (6-mercaptopurine or azathioprine). 
More complex cases require therapy with anti-TNF agents. 
Only few and preliminary data exist on cyclosporine A, tacro-
limus or methotrexate in fistulizing Crohn’s disease. There-
fore, these therapies should mainly be used as second-line 
therapies. Surgery is reserved for the treatment of perianal 
sepsis in the presence of abscesses and refractory disease or 
complications of fistulas, or used in combination with phar-
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20 years  [3] . One third of these patients had recurrent fis-
tulas, which emphasizes the extent of this complication 
in patients with CD. Crohn’s fistulas are thought to derive 
either from the anal glands at the dentate line in the anal 
canal or from ulcerations in the anus or rectum. Infec-
tions lead to abscess formation and subsequent tracking 
away from the anal canal. Fistulas are usually the conse-
quence of penetration of an abscess into an adjacent or-
gan or the skin. Thus, a fistula may initially present as an 
abscess, which upon spontaneous draining evolves into a 
fistulous tract.
 Fistulas can present with persistent anal pain, painful 
defecation, and as perianal openings with purulent dis-
charge. In approximately 10% of patients, perianal fistu-
lisation is the initial manifestation of CD  [5] . In some 
cases the formation of perianal fistulas might even pre-
cede the onset of CD by several years  [5] . The fistulous 
openings most commonly involve the perianal skin, but 
can also be in the groin, vulva, or scrotum.
 Fistulas can be classified based upon their anatomic 
extensions: simple fistulas are low (below the dentate 
line), have a single external opening, and are not painful 
with no evidence of rectovaginal fistula and with no evi-
dence of anorectal stricture. Complex fistulas are high 
(above the dentate line), may have multiple openings, are 
fistulas with evidence of abscess, and may be associated 
with pain, with the presence of a rectovaginal fistula, 
anorectal stricture or active rectal disease at endoscopy 
 [7] .
 The risk of fistula development is higher in patients 
with colonic CD, in particular in those with rectal in-
volvement, as compared with patients without colorectal 
disease. Diagnosis and treatment of fistulas in CD pa-
tients is often difficult. Once a patient with CD develops 
a fistula, achieving healing is a lengthy process and mul-
tiple relapses can be expected. With improvement of di-
agnosis and treatment over the last decade, the prospect 
changed dramatically. While 10 years ago, the goal of 
treatment was improvement of fistula drainage, this 
changed in our days to complete cessation of drainage or 
even fistula closure. Treatment has furthermore become 
a combined effort between medical physicians and sur-
geons. The aim of this article is to review mainly phar-
macological strategies that have been investigated in 
treatment of fistulizing CD. Some surgical strategies will 
be covered. One has to bear in mind that most published 
studies on fistulizing CD deal with therapy of external 
fistula (e.g. perianal) whereas data on therapy of internal 
fistula (e.g. enterovesical, enterouterine, or enterovagi-
nal) are scarce.
 Assessment and Scoring of Fistula in CD 
 The Crohn’s Disease Activity Index (CDAI)  [8] is of-
ten used in clinical trials. In the assessment of fistulas, 
however, this scoring system is not regarded as appropri-
ate  [9] . For instance, the CDAI only attributes 20 points 
to fistula regardless of the number and type of fistula. In 
1980, Present et al. proposed a score investigating the re-
duction or closure of external fistulas  [10] . This scoring 
system has not been validated in subsequent studies. In 
1995, an index to measure severity of fistulas in CD pa-
tients – the Perianal Disease Activity Index – was pub-
lished  [11] . This score comprises five categories (dis-
charge, pain, restriction of sexual activity, type of peri-
anal disease, and degree of induration). It has been 
validated in patients undergoing treatment with metro-
nidazole  [11, 12] . Furthermore, this index was used as a 
secondary end-point in the placebo-controlled trial of 
infliximab for the closure of perianal fistulas  [13] . Other 
therapeutic trials have used the finger compression tech-
nique to assess fistulas in CD  [10, 13–15] . This primary 
efficacy endpoint was defined as a reduction of 50% in 
the number of draining fistulas observed in two or more 
consecutive visits as assessed by the study investigator 
using gentle finger compression. Although this tech-
nique is very investigator dependent, it has been used in 
several placebo-controlled trials with infliximab, and ta-
crolimus  [13, 17, 27] . Studies that assess the reproducibil-
ity of this method compared with that of the PDAI are 
still desperately required. Thus, at this stage, there is no 
widely accepted and validated scoring system for fistulas 
in CD. The definition of ‘response to therapy’ varies from 
study to study. Furthermore, there is no consensus on 
when a fistula can be considered healed. This point is 
very crucial since several studies have demonstrated that 
fistula tracts persist after fistula closure and that com-
pletely healed fistulas can re-open after cessation of ther-
apy  [13, 16, 17] .
 Medical Therapies 
 A summary of different studies on medical therapy 
options in fistulizing CD is shown in  table 1  [10, 12, 13, 
15, 17–36] .
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First author Drug Regime Study type Year Patients Outcome Study 
period
Antibiotics
Bernstein [18] metro 20 mg/kg/day open label 1980 21 Clinical response (21/21) within 8 weeks; 
56% (10/18) complete healing 
10 weeks
Brandt [19] metro 20 mg/kg/day follow-up
study of [30]
1982 26 metro could only be successfully 
discontinued in 28% (5/18) of patients
up to 36 
months
Jakobovits [20] metro 1,000–1,500 mg/day open label 1984 8 20-fold reduction of draining fistulas;
50% reduction of detectable fistulous 
openings 
up to 6 
months
Thia [21] cipro
metro
1,000 mg of either drug RCT 2009 25 Reduction of >50% draining fistula:
30% (3/10) cipro, 0% (0/7) metro,
12.5% (1/8) placebo
10 weeks
Dejaco [12] metro + 
cipro + 
AZA
cipro:
500–1,000 mg/day
metro:
1,000–1,500 mg/day
for 8 weeks
AZA: 2–2.5 mg/kg/day
open label 2003 52 Reduction of >50% draining fistula:
48% AZA and metro/cipro, 
15% metro/cipro only
20 weeks
West [22] cipro + 
IFX
cipro (1,000 mg/day) +
IFX (5 mg/kg in week 6,
8, 12)
RCT 2004 24 Reduction of >50% draining fistula:
73% (8/11) cipro + IFX, 
39% (5/13) IFX alone
18 weeks
Immunosuppressive agents
Present [10] 6-MP 1.5 mg/kg/day RCT 1980 36 (40
fistulas)
31% (9/29) closure in 6-MP, 
6% (1/17) in placebo
52 weeks
Pearson [23] 6-MP,
AZA
n.a. meta-analysis
of 5 trials
1995 70 with
fistulas
Response rate (decreased discharge):
54% (22/41) AZA/6-MP, 
21% (6/29) placebo 
n.a.
Egan [24] cyclo 4 mg/kg/day i.v.,
then p.o.
retrospective 1998 9 77% (7/9) partial response up to 22 
weeks
Hanauer [25] cyclo 4 mg/kg/day i.v. for 6–10 
days, then 8 mg/kg/day p.o.
retrospective
(?)
1993 5 (12
fistulas)
83% (10/12) complete resolution up to 18 
months
Present [26] cyclo 4 mg/kg/day i.v., then
6–8 mg/kg/day p.o.
open label 1994 16 88% (14/16) initial response, 
44% (7/16) closure of fistulas
up to 37 
months
Sandborn [27] tacro 0.2 mg/kg/day or placebo RCT 2003 48 Reduction of >50% draining fistula
(improvement): 43% (9/21) tacro,
8% (2/25) placebo
10 weeks
Healing: 10% (2/21) tacro, 8% (2/25) 
placebo
González-Lama [28] tacro 0.05 mg/kg every 12 h open label 2005 10 40% (4/10) complete clinical response, 
50% (5/10) partial response
up to 24 
months
Mahadevan [29] MTX 25 mg/week i.m. for
3 months, then p.o.
retrospective
chart review
2003 16 25% (4/16) complete closure,
31% (5/16) partial closure
n.a.
Anti-TNF agents
Present [13] IFX 5 or 10 mg/kg or placebo
at weeks 0, 2, and 6
RCT 1999 94 Reduction of >50% draining fistula:
62% (39/62) IFX, 26% (8/31) placebo 
Complete closure: 
46% (29/63) IFX, 13% (4/31) placebo 
18 weeks
Sands [17] IFX 5 mg/kg at weeks 0, 2,
and 6, then every 8 weeks
RCT 2004 195
with IFX
response at
week 10/14
Reduction of >50% draining fistula:
46% (42/91) IFX, 23% (23/98) placebo
Complete response: 
36% (33/91) IFX, 19% (19/98) placebo
54 weeks
Table 1. S ummary of medical therapy options in fistulizing CD
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 Placebo Effect 
 Uncontrolled studies evaluating fistula response to 
treatment should be considered with caution since the 
natural history of fistulas is unpredictable. In placebo-
controlled trials a considerable response rate in the pla-
cebo arm has been observed in fistula treatment  [10, 13, 
27] . This has further been confirmed in a meta-analysis 
by Pascua et al., who reported an expected spontaneous 
fistula closure rate under placebo-therapy of 10%  [37] .
 Aminosalycilates and Corticosteroids 
 5-aminosalicylic acid has not been shown to be effec-
tive  [38] and should not be used in treatment of fistulizing 
CD  [39] . Glucocorticoids are an effective treatment for 
flares in CD patients. However, their use in fistula thera-
py in CD patients is limited. Studies evaluating cortico-
steroid treatment in CD patients with fistulas showed an 
even worse outcome regarding fistula activity and need 
for surgery in the corticosteroid treatment group when 
compared to patients not taking steroids  [40–42] .
First author Drug Regime Study type Year Patients Outcome Study 
period
Hanauer [30] ada weeks 0/2:
40 mg/20 mg s.c.;
80 mg/40 mg s.c.;
160 mg/80 mg s.c.
RCT 2006 32 with 
fistulas
Improvement: 
75% (3/4) on 40/20 mg
20% (2/10) on 80/40 mg 
8% (1/12) on 160/80 mg 
33% (2/6) on placebo 
Remission: 
75% (3/4) on 40/20 mg 
0% (0/10) on 80/40 mg 
0% (0/12) on 160/80 mg 
17% (1/6) on placebo
4 weeks
Sandborn [31] ada 160 mg s.c. week 0,
80 mg week 2
RCT 2007 45
with
fistulas
Fistula improvement: 15% (3/20) ada, 
20% (5/25) placebo 
Remission: 5% (1/20) ada, 8% (2/25) 
placebo 
4 weeks
Colombel [32] ada 80 mg/40 mg weeks 0/2,
40 mg e.o.w. or e.w.
RCT 2007 117 Complete closure: 
33% (23/70) ada
13% (6/47) placebo
56 weeks
Colombel [33] ada 80 mg s.c. week 0,
40 mg s.c. week 2, then
40 mg e.o.w. or e.w.
open label
extension of
[36]
2009 117 Sustained fistula healing: 
90% (28/31) ada
2 years
Sandborn [34] CZP 400 mg s.c. weeks 0, 2,
4, then every 4 weeks
RCT 2007 107 with
fistulas
Fistula closure: 
30% (14/46) CZP
31 (19/61) placebo 
26 weeks
Schreiber [35] CZP 400 mg s.c. weeks 0, 2,
4, then every 4 weeks
RCT 2007 58 with
fistulas
Fistula closure: 
54% (15/28) CZP 
43% (13/30) placebo
26 weeks
Schoepfer [15] CZP 400 mg s.c. weeks 0, 2,
4, then every 4 weeks
open label 2009 11 with
fistulas
(total 27 
fistulas)
Reduction of >50% draining fistula:
72% (8/11)
6 weeks
Other medical therapies
Fukuda [36] oral 
spheric 
adsorptive 
carbon 
(AST)
2 g t.i.d. for 8 weeks RCT 2008 57 Improvement: 
37% (10/27) AST, 10% (3/30) placebo 
Remission: 
29.6% (8/27) AST, 6.7% (2/30) placebo
8 weeks
A ll randomized controlled trials (RCT) were double-blind and placebo-controlled. 
metro = Metronidazole; cipro = ciprofloxacin; AZA = azathioprine; 6-MP = 6-mercaptopurine; cyclo = cyclosporine A; tacro = tacrolimus; MTX = 
methotrexate; IFX = infliximab; ada = adalimumab; CZP = certolizumab pegol; e.o.w. = every other week; e.w. = every week.; t.i.d. = three times a day.
Table 1 (continued)
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 Antibiotics 
 Antibiotics are efficacious in the short-term manage-
ment of fistulas and their associated infections, but the 
recurrence rate at withdrawal is high and complete heal-
ing is not frequently achieved with antibiotics alone. Nev-
ertheless, antibiotics represent a widely-used first-line 
treatment option for fistulas in CD patients. Despite their 
widespread use, not many controlled trials regarding ef-
ficacy in the treatment of fistulizing CD have been pub-
lished. The most widely used antibiotic is metronidazole 
 [18–20, 43] . When metronidazole is used, a response can 
be expected after 6–8 weeks. The therapy usually is con-
tinued for 3–4 months. Metronidazole was shown to 
close fistulas in up to 83% in an open-label case series  [18] . 
Although useful in short-term treatment, there are prob-
lems associated with long-term use of metronidazole. 
These include nausea, glossitis, metallic taste, and disul-
firam-like response to alcohol intake. Particularly at 
higher doses ( 1 750 mg daily), peripheral neuropathy and 
paresthesias limit the use of this agent for long-term 
treatment  [19] .
 Ciprofloxacin has only been evaluated for the treat-
ment of perianal CD in small, uncontrolled studies  [44, 
45] . Headaches, nausea, diarrhea and rash are known ad-
verse reactions with ciprofloxacin. Spontaneous tendon 
rupture (Achilles tendon) has also been reported in pa-
tients using long-term ciprofloxacin  [46] . There are no 
long-term fistula closure data supporting the use of anti-
biotics and withdrawal of antibiotics leads to re-exacer-
bation of the disease. Therefore, the use of antibiotics in 
combination with other therapies has been evaluated. An 
open-label prospective study was designed to treat pa-
tients with metronidazole and ciprofloxacin for 8 weeks. 
Some of the patients were already on azathioprine thera-
py, whereas others started on azathioprine after 8 weeks 
of antibiotic therapy  [11] . Based on their results, the au-
thors conclude that antibiotics might provide a bridge 
strategy for azathioprine therapy. Using ciprofloxacin in 
combination with infliximab was recently evaluated in a 
double-blind placebo-controlled study  [22] . All patients 
received infliximab and were randomized to receive ei-
ther ciprofloxacin of placebo. There was a trend for pa-
tients treated with ciprofloxacin to respond more than 
those on placebo therapy (OR = 2.37, p = 0.07) suggesting 
that ciprofloxacin in combination with infliximab may 
be more effective than infliximab alone.
 Immunosuppressive Agents 
 Present et al. described the efficacy and safety of 
6-mercaptopurine in the treatment of CD  [47] . Among 
this collective, 40 fistulas were observed in 36 patients. 
Thirty-one percent of the fistulas closed completely dur-
ing the treatment with 6-mercaptopurine, versus only 6% 
with placebo. The onset of response was often delayed, 
with 32% of the patients taking longer than three months 
to respond. A meta-analysis of the controlled trials with 
6-mercaptopurin and azathioprine in CD that included 
patients with fistulas has shown a response rate to these 
drugs of 54% compared with 21% for placebo  [23] . We can 
conclude from these studies that immunosuppression 
with azathioprine or 6-mercaptopurine is effective both 
in closing and in maintaining closure of fistulas. The dos-
es should be at 2.0–3.0 mg/kg/day of azathioprine and 
1.5mg/kg/day of 6-MP. Nevertheless, those agents pro-
duce fistula closure in only a minority of patients, but 
inflammation, discharge and discomfort often are re-
duced markedly. Adverse events include pancreatitis 
(3%), allergic reactions, infections, leucopenia, and drug-
induced hepatitis. Intravenous cyclosporine  [24–26] and 
oral tacrolimus  [27, 28, 48] both improve or heal a sub-
stantial proportion of patients short-term, but they often 
relapse on stopping the drug. A study evaluating intrave-
nous cyclosporine (4mg/kg/day) showed that 14 out of 16 
patients (88%) responded. Complete closure was ob-
served in 7 (44%) and a moderate improvement in the 
other 7 (44%)  [26] . Two other uncontrolled studies ob-
tained similar results  [24, 25] . Clinical response was seen 
as soon as one week in those studies, but transition to oral 
therapy or discontinuation of cyclosporine was associat-
ed with a high relapse rate. Based on these studies, cyclo-
sporine can be used in the treatment of fistulizing CD, 
but only as a bridging therapy to azathiorpine/6-mercap-
topurine or methotrexate therapy. The side effects of cy-
closporine include: hypertension, headache, hirsutism, 
hypertrichosis, seizure, hypertriglyceridemia, nausea, 
gingival hyperplasia, tremor, paresthesia, increased inci-
dence of infection and nephropathy  [49] . The only con-
trolled trial of oral tacrolimus (0.2 mg/kg/day) showed a 
significantly positive effect on improvement compared 
with placebo, but did not show fistula healing when pa-
tients were treated for 10 weeks  [27] . The authors found 
no evidence of efficacy in patients with abdominal fistu-
las. A more recent open study by González-Lama et al. 
 [28] , of 10 patients showed substantial healing, with 40% 
achieving complete clinical response and 50% achieving 
a partial response, but patients were treated for 6 to 24 
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months. Long-term therapy may, therefore, be required 
for achieving healing using this medication. Adverse 
events of tacrolimus therapy include headache, increased 
serum creatinine levels, insomnia, leg cramps, paresthe-
sias and tremor, which could be managed with dose re-
duction. Methotrexate has been studied in CD patients 
with fistulas. In a small study in 16 patients, 4 (25%) had 
complete closure of fistulas and 5 (31%) a partial response 
 [29] . Therefore, methotrexate should be tried, especially 
in patients not responding to azathioprine/6-mercapto-
purine.
 Anti-TNF Agents 
 In the first anti-TNF-alpha antibody trial for fistuliz-
ing CD, Present et al.  [13] investigated 94 patients who 
received three infusions of infliximab therapy. Most pa-
tients had perianal fistulas. Sixty-eight percent of patients 
had a clinical response, with 55% closing all fistulas. The 
ACCENT 2 trial has extended these findings  [17] . Of 306 
actively treated patients, 64% had an initial response with 
50% or more of fistulas closing. Of these initial respond-
ers treated with infliximab, 36% were healed at one year 
after regular infliximab treatment, compared with 19% 
treated with placebo after the initial response. A post hoc 
analysis was performed to determine the efficacy and 
safety of infliximab in women with rectovaginal fistulas 
 [50] . After the first three infusions, 61 and 45% of recto-
vaginal fistulas were closed at week 10 and 14, respec-
tively. Among responders, 72% of rectovaginal fistulas 
were no longer draining at week 14. The duration of rec-
tovaginal closure was longer in the infliximab mainte-
nance group (median 46 weeks) than in the placebo group 
(33 weeks). Side effects include increased risk of infec-
tions (including tuberculosis), malignancies and immu-
nological reactions (infusion reactions, delayed hyper-
sensitivity reactions), and in rare cases drug-induced lu-
pus after exposure to infliximab. In two multicenter 
trials evaluating infliximab for induction and mainte-
nance  [13, 50] therapy for fistulizing CD, 11% and 15% 
developed abscesses related to their fistulae. Abscess for-
mation likely occurred in these patients due to closure of 
the cutaneous opening of the fistula tract prior to the 
opening from the gastrointestinal tract. Adalimumab is 
a fully humanized antibody to TNF. In a recent large pla-
cebo-controlled Crohn’s trial of adalimumab, 113 pa-
tients also had perianal fistulas. Two thirds of patients 
had one fistula whereas one third of patients had more 
than one fistula. Patients received adalimumab 80 mg 
initially, then 40 mg two weeks later, followed by 40 mg 
every two weeks, 40 mg weekly, or placebo. Patients with 
draining fistulas were evaluated for healing at week 26 
and 56. Thirty percent (21 of 70) of all randomized pa-
tients on active adalimumab maintenance treatment had 
complete healing at both time points, compared with 13% 
(6 of 47) on placebo maintenance  [32] . Adalimumab rep-
resents an option for patients who have lost response or 
who have become intolerant to infliximab. Certolizumab 
pegol is a humanized TNF antibody with a pegylated Fab 
fragment. This compound has been evaluated in two 
large studies (PRECiSE 1 and 2) in patients with CD  [34, 
35] . In those two studies, only a small number of included 
patients had a fistulizing disease and complete fistula 
healing was not statistically different between the place-
bo group and the certolizumab pegol treatment group. A 
small open-label study showed a reduction of  1 50% 
draining fistulas of 72% at week 6  [15] .
 Other Therapies 
 Another approach that has been described is treat-
ment with an oral formulation of adsorptive carbon 
[AST-120 (Kremezin), Kureha Corp., Tokyo, Japan]. A 
placebo-controlled trial involving 62 patients with in-
tractable anal fistulas due to CD found significantly 
higher rates of improvement (37 vs. 10%) and remission 
(30 vs. 7%) after eight weeks of treatment  [36] . The drug, 
which is approved in Japan for treatment of chronic kid-
ney disease, adsorbs some low-molecular weight sub-
stances such as uremic toxins. The authors hypothesized 
that intraluminal binding of some of these toxins may 
help to heal fistulas.
 Surgical Management 
 The goal of surgical therapy is to eradicate the fistula 
while preserving fecal continence. The surgical approach 
depends upon the type of fistula. In patients with inter-
sphincteric fistulas, the fistula tract can be laid open in 
the form of a primary fistulotomy. The base of the wound 
is then curetted and left open to heal by secondary inten-
tion. The traditional mainstay of fistula treatment has 
been drainage, and use of a non-dissolving thread (seton) 
inserted loosely through the fistula track to maintain pa-
tency. The seton can be removed when the track is healing 
or left in situ long term if healing is not occurring. This 
surgical approach prevents sphincter damage by prevent-
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ing recurrent abscess formation. Up to 20–80%  of CD pa-
tients with perianal fistulas will eventually require sur-
gery  [3] and about 30% of patients with complicated peri-
anal CD may eventually require a permanent stoma  [51, 
52] . The presence of active proctitis reduces the chance of 
fistula healing and the proctitis needs to be treated ag-
gressively if fistula healing is to be achieved  [53] . In an 
intractable situation in which there is extensive perianal 
disease and seton drainage provides inadequate, the cre-
ation of a stoma, to divert the fecal stream away from the 
anal canal sometimes is considered. In one series this lead 
to early remission of anal disease in 81% of patients, but 
three quarters of these patients relapsed at a median of 2 
years after stoma formation  [54] . Another technique used 
for high trans-sphincteric fistulas is a partial fistulecto-
my and endoanal advancement flap. With this technique 
the fistula is cored out from the external opening up to 
the external circumference of the sphincter muscle. The 
remaining portion of the tract is then curetted and 
cleaned of any residual epithelial or granulation tissue. 
The internal opening is cauterized and curetted and then 
a proximal flap of mucosa is developed and slid over the 
internal opening. Usually the underlying rectal wall is 
also closed. Results with this procedure are varied but the 
technique allows for treatment of these high fistulas 
without division of the sphincter complex. A relatively 
new treatment for high trans-sphincteric or other com-
plicated fistulas is injection of fibrin glue. The fibrin glue 
can be made ahead of time in the blood bank, or a com-
mercial preparation is available. Early reports have de-
scribed eradication of fistulas in up to 60% of patients 
with complex tracts  [55–57] . However, recrudescence oc-
curs commonly. One of the largest reports, for example, 
included 42 patients, most of whom had deep trans-
sphincteric fistulas  [58] . Durable healing was achieved in 
only 31% of patients. Nevertheless, the authors concluded 
that fibrin glue was still a reasonable option given its low 
morbidity and relative simplicity. Fibrin glue has also 
been used successfully in patients with anal fistulas re-
lated to CD  [59] . Other adhesive products are also being 
developed  [60] .
 Conclusion 
 Perianal fistulas lead to substantial physical and emo-
tional distress because of pain, discharge, incontinence, 
perianal and genital disfigurement, and slow resolution 
even with treatment. With an expected spontaneous 
healing rate of only 10%, fistulizing CD requires a com-
prehensive strategy with a medical and possible surgical 
approach. Antibiotics are indicated and both ciprofloxa-
cin and metronidazole are used in patients with fistuliz-
ing CD. Azathioprin/6-mercaptopurin or methotrexate 
should be given early in the disease. In the case of resis-
tance or intolerance, infliximab should be initiated. Cy-
closporin and tacrolimus should be tried in patients who 
fail to respond to infliximab. Synergistic strategies be-
tween medical physicians and surgeons are desperately 
needed and should be evaluated in controlled trials.
 Acknowledgements 
 This study was supported by a research grant from the Swiss 
National Science Foundation grant 320000-114009/1 (to S.R.V.), 
grant No. 310030-120312 (to G.R.), 3347CO-108792 (Swiss IBD 
Cohort) and a grant from the Zurich Center of Integrative Hu-
man Physiology.
 Disclosure Statement 
 S.R.V. has received grant support from Abbott, UCB and Es-
sex. G.R. discloses grant support from Abbott, Ardeypharm, Es-
sex, FALK, Flamentera, Novartis, Tillots, UCB and Zeller. 
 References 
 1 McKee RF, Keenan RA: Perianal Crohn’s 
disease: is it all bad news? Dis Colon Rectum 
1996; 39: 136. 
 2 van Dongen LM, Lubbers EJ: Perianal fistu-
las in patients with Crohn’s disease. Arch 
Surg 1986; 121: 1187. 
 3 Schwartz DA, Loftus EV Jr, Tremaine WJ, 
Panaccione R, Harmsen WS, Zinsmeister 
AR, Sandborn WJ: The natural history of fis-
tulizing Crohn’s disease in Olmsted Coun-
ty, Minnesota. Gastroenterology 2002; 122: 
 875–880. 
 4 Judge TA, Lichtenstein GR: Treatment of fis-
tulising Crohn’s disease. Gastroenterol Clin 
North Am 2004; 33: 421–454. 
 5 Hellers G, Bergstrand O, Ewerth S, Holm-
ström B: Occurrence and outcome after pri-
mary treatment of anal fistulae in Crohn’s 
disease. Gut 1980; 21: 525–527. 
 6 Solomon MJ: Fistulae and abscesses in symp-
tomatic perianal Crohn’s disease. Int J 
Colorectal Dis 1996; 11: 222–226. 
 7 Sandborn WJ, Fazio VW, Feagan BG, 
Hanauer SB: AGA technical review on peri-
anal Crohn’s disease. Gastroenterology 
2003; 125: 1508–1530. 
 8 Best WR, Becktel JM, Singleton JW, Kern F 
Jr: Development of a Crohn’s disease activity 
index. National Cooperative Crohn’s Dis-
ease Study. Gastroenterology 1976; 70: 439–
444. 
 Fistula Treatment: The Unresolved 
Challenge 
Dig Dis 2010;28:556–564 563
 9 Sandborn WJ, Feagan BG, Hanauer SB, 
Lochs H, Löfberg R, Modigliani R, Present 
DH, Rutgeerts P, Schölmerich J, Stange EF, 
Sutherland LR: A review of activity indices 
and efficacy endpoints for clinical trials of 
medical therapy in adults with Crohn’s dis-
ease. Gastroenterology 2002; 122: 512–530. 
 10 Present DH, Korelitz BI, Wisch N, Glass JL, 
Sachar DB, Pasternack BS: Treatment of 
Crohn’s disease with 6-mercaptopurine: a 
long-term, randomized, double-blind study. 
N Engl J Med 1980; 302: 981–987. 
 11 Irvine EJ: Usual therapy improves perianal 
Crohn’s disease as measured by a new disease 
activity index. McMaster IBD Study Group. 
J Clin Gastroenterol 1995; 20: 27–32. 
 12 Dejaco C, Harrer M, Waldhoer T, Miehsler 
W, Vogelsang H, Reinisch W: Antibiotics 
and azathioprine for the treatment of peri-
anal fistulas in Crohn’s disease. Aliment 
Pharmacol Ther 2003; 18: 1113–1120. 
 13 Present DH, Rutgeerts P, Targan S, Hanauer 
SB, Mayer L, van Hogezand RA, Podolsky 
DK, Sands BE, Braakman T, DeWood KL, 
Schaibl TF, van Deventer SJ: Infliximab for 
the treatment of fistulas with Crohn’s dis-
ease. N Engl J Med 1999; 340: 1398–1405. 
 14 Hinojosa J, Gomollon F, Garcia S, Bastida G, 
Cabriada JL, Saro C, Ceballos D, Penate M, 
Gassul MA: Efficacy and safety of short-
term adalimumab treatment in patients with 
active Crohn’s disease who lost response or 
showed intolerance to infliximab: a prospec-
tive, open-label, multicentre trial. Aliment 
Pharmacol Ther 2007; 25: 409–418. 
 15 Schoepfer AM, Vavricka SR, Binek J, Felley 
C, Geyer M, Manz M, Rogler G, de Saussure 
P, Sauter B, Seibold F, Straumann A, Michet-
ti P: Efficacy and safety of certolizumab
pegol induction therapy in an unselected 
Crohn’s disease population: Results of the 
FACTS survey. Inflamm Bowel Dis 2010; 16: 
 933–938. 
 16 Ardizzone S, Maconi G, Colombo E, Man-
zionna G, Bollani S, Bianchi Porro G: Peri-
anal fistulae following infliximab treatment: 
clinical and endosonographic outcome. In-
flamm Bowel Dis 2004; 10: 91–96. 
 17 Sands BE, Anderson FH, Bernstein CN, 
Chey WY, Feagan BG, Fedorak RN, Kamm 
MA, Korzenik JR, Lashner BA, Wild G, Wolf 
DC, Marsters PA, Travers SB, Blank MA, van 
Deventer SJ: Infliximab maintenance thera-
py for fistulazing Crohn’s disease. N Engl J 
Med 2004; 350: 876–885. 
 18 Bernstein LH, Frank MS, Brandt LJ, Boley
SJ: Healing of perineal Crohn’s disease with 
metronidazole. Gastroenterology 1980; 79: 
 357–365. 
 19 Brandt LJ, Bernstein LH, Boley SJ, Frank MS: 
Metronidazole therapy for perineal Crohn’s 
disease: a follow-up study. Gastroenterology 
1982; 83: 383–387. 
 20 Jakobovits J, Schuster MM: Metronidazole 
therapy for Crohn’s disease and associated 
fistulae. Am J Gastroenterol 1984; 79: 533–
540. 
 21 Thia KT, Mahadewan U, Feagan BG, Wong 
CW, Cockeram A, Bitton A, Bernstein C, 
Sandborn WJ: Cirpofloxacin or metronida-
zole for the treatment of perianal fistulas
in patients with Crohn’s disease: a random-
ized, double-blind, placebo-controlled pilot 
study. Inflamm Bowel Dis 2009; 15: 17–24. 
 22 West RL, van der Woude CJ, Hansen BE, 
Felt-Bersma RJ, van Tilburg AJ, Drapers JA, 
Kuipers J: Clinical and endosonographic ef-
fect of ciprofloxacin on the treatment of peri-
anal fistulae in Crohn’s disease with inflix-
imab: a double-blind placebo-controlled 
study. Aliment Pharmacol Ther 2004; 20: 
 1329–1336. 
 23 Pearson DC, May GR, Fick GH, Sutherland 
LR: Azathioprine and 6-mercaptopurine in 
Crohn’s disease: a meta-analysis. Ann Intern 
Med 1995; 123: 132–142. 
 24 Egan LJ, Sandborn WJ, Tremaine WJ: Clini-
cal outcome following treatment of refrac-
tory inflammatory and fistulising Crohn’s 
disease with intravenous cyclosporine. Am J 
Gastroenterol 1998; 93: 442–448. 
 25 Hanauer SB, Smith MB: Rapid closure of 
Crohn’s disease fistulas with continuous in-
travenous cyclosporine. Am J Gastroenterol 
1993; 88: 646–649. 
 26 Present DH, Lichtiger S: Efficacy of cyclo-
sporine in treatment of fistula of Crohn’s dis-
ease. Dig Dis Sci 1994; 39: 374–380. 
 27 Sandborn WJ, Present DH, Isaacs KL, Wolf 
DC, Greenberg E, Hanauer SB, Feagan BG, 
Mayer L, Johnson T, Galanko J, Martin C, 
Sandler RS: Tacrolimus for the treatment of 
fistulas in patients with Crohn’s disease: a 
randomized, placebo-controlled trial. Gas-
troenterology 2003; 125: 380–388. 
 28 González-Lama Y, Abreu L, Vera MI, Pastra-
na M, Tabernero S, Revilla J, Durán JG, Es-
cartin P: Long-term oral tacrolimus ther-
apy in refractory to infliximab fistulizing 
Crohn’s disease. Inflamm Bowel Dis 2005; 
 11: 8–15. 
 29 Mahadevan U, Marion JF, Present DH: Fis-
tula response to methotrexate in Crohn’s dis-
ease: a case series. Aliment Pharmacol Ther 
2003; 18: 1003–1008. 
 30 Hanauer SB, Sandborn WJ, Rutgeerts P, Fe-
dorak RN, Lukas M, Macintosh D, Panac-
cione R, Wolf D, Pollack P: Human anti-tu-
mor necrosis factor monoclonal antibody 
(adalimumab) in Crohn’s disease: the CLAS-
SIC-I trial. Gastroenterology 2006; 10: 323–
333. 
 31 Sandborn WJ, Rutgeerts P, Enns R, Hanauer 
SB, Colombel AF, Panaccione R, D’Haens G, 
Li J, Rosenfeld MR, Kent JD, Pollack PF: 
Adalimumab induction therapy for Crohn 
disease previously treated with infliximab. 
Ann Intern Med 2007; 146: 829–838. 
 32 Colombel JF, Sandborn WJ, Rutgeerts P, 
Enns R, Hanauer SB, Panaccione R, Schrei-
ber S, Byczkowski D, Li J, Kent JD, Pollack 
PF: Adalimumab for maintenance of clinical 
response and remission in patients with 
Crohn’s disease: the CHARM Trial. Gastro-
enterology 2007; 132: 52–65. 
 33 Colombel JF, Schwartz DA, Sandborn WJ, 
Kamm MA, D’Haens G, Rutgeerts P, Enns R, 
Panaccione R, Schreiber S, Li J, Kent JD, Lo-
max KG, Pollack PF: Adalimumab for the 
treatment of fistulas in patients with Crohn’s 
disease. Gut 2009; 5: 940–948. 
 34 Sandborn WJ, Feagan BG, Stoinov S, Honi-
ball PJ, Rutgeerts P, Mason D, Bloomfield R, 
Schreiber S: Certolizumab pegol for the 
treatment of Crohn’s disease. N Engl J Med 
2007; 357: 228–238. 
 35 Schreiber S, Khaliq-Kareemi M, Lawrance 
IC, Thomson O, Hanauer SB, McColm J, 
Bloomfield R, Sandbron WJ: Maintenance 
therapy with certolizumab pegol for Crohn’s 
disease. N Engl J Med 2007; 357: 239–250. 
 36 Fukuda Y, Takazoe M, Sugita A, Kosaka T, 
Kinjo F, Otani Y, Fuji H, Kohanei K, Maki-
yama K, Nakamura T, et al: Oral spheric ad-
sorptive carbon for the treatment of intrac-
table anal fistulas in Crohn’s disease: a 
multicenter, randomized, double-blind, pla-
cebo-controlled trial. Am J Gastroenterol 
2008; 103: 1721–1729. 
 37 Pascua M, Su C, Lewis JD, Brensinger C,
Lichtenstein GR: Meta-analysis: factor pre-
dicting post-operative recurrence with pla-
cebo therapy in patients with Crohn’s dis-
ease. Aliment Pharmacol Ther 2008; 28: 545–
556. 
 38 Nielsen OH, Munck LK: Drug insight: ami-
nosalicylates for the treatment of IBD. Nat 
Clin Pract Gastroenterol Hepatol 2007; 4: 
 160–170. 
 39 Travis SP, Stange EF, Lemann M, Oresland T, 
Chowers Y, Forbes A, D’Haens G, Kitis G, 
Cortot A, Prantera C, Marteau P, Colombel 
JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen 
J, Starlinger M. Mortensen NJ: European ev-
idence based consensus on the diagnosis and 
management of Crohn’s disease: current 
management. Gut 2006; 55(suppl 1):i16–i35. 
 40 Jones JH, Lennard-Jones E: Corticosteroids 
and corticotropin in the treatment of Crohn’s 
disease. Gut 1966; 7: 181–187. 
 41 Sparberg M, Kirsner JB: Long-term cortico-
steroid therapy for regional enteritis: an 
analysis off 58 courses in 54 patients. Am J 
Dig Dis 1966; 11: 865–880. 
 42 Malchow H, Ewe K, Brandes JW, Goebell
H, Ehms H, Sommer H, Jesdinsky H: Euro-
pean Cooperative Crohn’s Disease Study 
(ECCDS): results of drug treatment. Gastro-
enterology 1984; 86: 249–266. 
 43 Schneider MU, Laudage G, Guggenmoos-
Holzmann I, Riemann JF: Metranidazole in 
the treatment of Crohn’s disease: results of a 
controlled randomized prospective study. 
Dtsch Med Wochenschr 1985;  110:  1724–
1730. 
 Vavricka/Rogler
 
Dig Dis 2010;28:556–564564
 44 Turunen U, Farkkila M, Seppala K: Long-
term treatment of peri-anal or fistulous 
Crohn’s disease with ciprofloxacin. Scand J 
Gastroenterol 1989; 24(suppl 48):144. 
 45 Wolf J: Ciprofloxacin may be useful in 
Crohn’s disease. Gastroenterology 1990; 
 98:A212. 
 46 Casparian JM, Luchi M, Moffat RE, Hin-
thorn D: Quinolones and tendon ruptures. 
South Med J 2000; 93: 488–491. 
 47 Present DH, Korelitz BI, Wisch N, Glass JL, 
Sachar DB, Pasternack BS: Treatment of 
Crohn’s disease with 6-mercaptopurine: a 
long-term, randomized, double-blind study. 
N Eng J Med 1980; 302: 981–987. 
 48 Ng SC, Arebi N, Kamm MA: Medium-term 
results of oral tacrolimus for treatment of re-
fractory inflammatory bowel disease. In-
flamm Bowel Dis 2007; 13: 129–134. 
 49 Sandborn WJ: A critical review of cyclo-
sporine therapy in inflammatory bowel dis-
ease. Inflamm Bowel Dis 1995; 1: 48–63. 
 50 Sands BE, Blank MA; Patel K, van Deventer 
SJ: Long-term treatment of rectovaginal fis-
tulas in Crohn’s disease: response to inflix-
imab in the ACCENT II study. Clin Gastro-
enterol Hepatol 2004; 2: 912–920. 
 51 Mueller MH, Geis M, Glatzle J, Kasparek M, 
Meile T, Jehle EC, Kreis ME; Zittel TT: Risk 
of fecal diversion in complicated perianal 
Crohn’s disease. J Gastrointest Surg 2007; 11: 
 529–537. 
 52 Loffler T, Welsch T, Muhl S, Hinz U, Schmidt 
J, Kienle P: Long-term success rate after sur-
gical treatment of anorectal and rectovaginal 
fistulas in Crohn’s disease. Int J Colorectal 
Dis 2009; 24: 521–526. 
 53 Kamm M, Siew CN: Perianal fistulising 
Crohn’s disease: a call to action. Clin Gastro-
enterol Hepatol 2006; 6: 7–10. 
 54 Yamamoto T, Allan RN, Keighley MR: Effect 
of fecal diversion alone on perianal Crohn’s 
disease. World J Surg 2000; 24: 1258–1262. 
 55 Venkatesh KS, Ramanujam P: Fibrin glue ap-
plication in the treatment of recurrent ano-
rectal fistulas. Dis Colon Rectum 1999; 42: 
 1136. 
 56 Sentovich SM: Fibrin glue for anal fistulas: 
long-term results. Dis Colon Rectum 2003; 
 46: 498. 
 57 Zmora O, Neufeld D, Ziv Y, Tulchinsky H, 
Scott D, Khaikin M, Stepansky A, Rabau M, 
Koller M: Prospective, multicenter evalua-
tion of highly concentrated fibrin glue in the 
treatment of complex cryptogenic perianal 
fistulas. Dis Colon Rectum 2005; 48: 2167. 
 58 Loungnarath R, Dietz DW, Mutch MG, Birn-
baum EH, Kodner IJ, Fleshman JW: Fibrin 
glue treatment of complex anal fistulas has 
low success rate. Dis Colon Rectum 2004; 47: 
 432. 
 59 Vitton V, Gasmi M, Barthet M, Desjeux A, 
Orsoni P, Grimaud JC: Long-term healing of 
Crohn’s anal fistulas with fibrin glue injec-
tion. Aliment Pharmacol Ther 2005; 21: 1453. 
 60 de la Portilla F, Rada R, León E, Cisneros N, 
Maldonado VH, Espinosa E: Evaluation of 
the use of BioGlue in the treatment of high 
anal fistulas: preliminary results of a pilot 
study. Dis Colon Rectum 2007; 50: 218. 
 
